Recruiting PHASE2 Actinic Keratosis

New treatment option for Actinic Keratosis

Official title The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

ClinicalTrials.gov ID: NCT06778434

What this study is testing

What is Imipramine?

Imipramine is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for actinic keratosis.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The purpose of this study is to test the use of topical imipramine in combination with topical photodynamic therapy's (PDT) effect on the effectiveness and pain immunosuppression following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis or "AK") on their skin.
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

  • Adult Males and Females ages 18 and older who are patients at the Dayton VAMC Dermatology clinics
  • Skin type must be "Fair", Fitzpatrick type I or II, due to the presence of actinic damage in this population.
  • people must have a VA physician's order to receive PDT treatment on their forearms.
  • Willing to participate and understand the informed consent document.
  • Willing to avoid excess sun exposure/tanning beds to the area to be treated with PDT.

You likely can't join if

  • Currently taking any tricyclic antidepressants (TCAs)
  • Currently taking any selective serotonin reuptake inhibitor (SSRI)
  • Has Porphyria
  • Large tattoos in areas to be tested
  • Pregnancy or nursing
  • Taking any oral or topical medications that could interfere with the PDT
See the full eligibility criteria
Who can join
  • Adult Males and Females ages 18 and older who are patients at the Dayton VAMC Dermatology clinics
  • Skin type must be "Fair", Fitzpatrick type I or II, due to the presence of actinic damage in this population.
  • people must have a VA physician's order to receive PDT treatment on their forearms.
  • Willing to participate and understand the informed consent document.
  • Willing to avoid excess sun exposure/tanning beds to the area to be treated with PDT.
  • Has stable transportation to attend study visits at DVA
What rules you out
  • Currently taking any tricyclic antidepressants (TCAs)
  • Currently taking any selective serotonin reuptake inhibitor (SSRI)
  • Has Porphyria
  • Large tattoos in areas to be tested
  • Pregnancy or nursing
  • Taking any oral or topical medications that could interfere with the PDT
  • Active rashes in the areas

The study team makes the final eligibility decision.

Where it's taking place

  • Dayton, Ohio, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Dayton, Ohio, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.